Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00319865
Status:
UNKNOWN
Last Update Posted:
2006-04-27
First Post:
2006-04-28
Brief Title:
PAD Combination Therapy Followed by ThalDex for Relapsed or Refractory Multiple Myeloma
Sponsor:
Korean Multiple Myeloma Working Party
Organization:
Korean Multiple Myeloma Working Party
Study Overview
Official Title:
PS-341 Bortezomib Velcade Adriamycin and Dexamethasone PAD Combination Therapy Followed by Thalidomide With Dexamethasone ThalDex for Relapsed or Refractory Multiple Myeloma
Status:
UNKNOWN
Status Verified Date:
2006-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prospective multicenter phase 2 study using PAD and ThalDex combination sequentially
Detailed Description:
Although the overall survival was improved with the introduction of high dose therapy with autologous hematopoetic stem cell transplantationit remains as a incurable disease Most patients ultimately relapse Recenlty targeted therapy using novel agents such as bortezomib and thalidomide shows the possibility of improved in this situation Among them PAD Velcade AdriamycinDexamethasone showed highest response rate PAD does not show any cross resiatance with another effective combination thalidomide plus dexamethasone
We desined prospective multicenter phase 2 study using these combination sequentially
We desined prospective multicenter phase 2 study using these combination sequentially
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None